Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortCDK4/6 inhibitor with QT effects, for hormone-positive breast cancer.CDK4/6 inhibitor for hormone-positive breast cancer.
Body systemCancerCancer
Drug classCDK4/6 inhibitorsCDK4/6 inhibitors
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesHormone-positive, HER2-negative advanced breast cancerHormone-positive, HER2-negative advanced breast cancer
How it worksStops breast cancer cells from dividing.Stops breast cancer cells from dividing.
Starts workingDepends on the cancer and regimenDepends on the cancer and regimen
Half-lifeAbout 32 hoursAbout 29 hours
Typical adult doseDosed by your cancer team according to the treatment protocol.Dosed by your cancer team according to the treatment protocol.
FormsTabletCapsule, Tablet
Common side effectsLow white cells, Nausea, Tiredness, Diarrhoea, Hair thinningLow white cells, Tiredness, Nausea, Mouth sores, Hair thinning, Infections
Serious side effectsQT prolongation, Liver injury, Severe skin reactionsFebrile neutropenia, Lung inflammation, Blood clots
Don't take ifLong QT or uncontrolled heart rhythm disease; Pregnancy; Severe liver impairmentPregnancy; Severe liver impairment
AlcoholBest to limit. Alcohol can add to tiredness.Best to limit. Alcohol can add to tiredness.
PregnancyUsually avoidedAvoid.Usually avoidedAvoid.
BreastfeedingUsually avoidedAvoid.Usually avoidedAvoid.
In use since——
Brand namesUnited States: KisqaliUnited Kingdom: KisqaliIndia: Kisqali, Ribociclib (generic)United States: IbranceUnited Kingdom: IbranceIndia: Ibrance, Palbociclib (generic)
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H
ATC codeL01EF02L01EF01

Taken together

  • ModerateRibociclib + Palbociclib: Added bone marrow suppression

    Both can lower white cells, red cells or platelets; together the risk of infection and bleeding rises.

Open in the interaction checker